|
Chapter 1 Nanocarriers in drug delivery: Classification, properties, and targeted drug delivery applications |
|
|
1 | (24) |
|
|
1 | (1) |
|
Classification of nanocarriers |
|
|
2 | (1) |
|
Organic and polymer-based nanocarriers |
|
|
3 | (6) |
|
|
9 | (3) |
|
Absorption mechanisms of nanocarriers-based drugs |
|
|
12 | (1) |
|
|
13 | (1) |
|
|
14 | (1) |
|
Release mechanisms of nutraceuticals from nanocarrier |
|
|
15 | (1) |
|
|
16 | (1) |
|
|
17 | (8) |
|
Chapter 2 Nanocarriers systems for brain targeted drug delivery and diagnosis |
|
|
25 | (20) |
|
|
25 | (1) |
|
The blood-brain barrier (BBB) |
|
|
26 | (2) |
|
Barriers to brain drug delivery |
|
|
28 | (1) |
|
Nanocarriers for brain drug delivery |
|
|
29 | (2) |
|
|
31 | (1) |
|
|
31 | (1) |
|
Solid lipid nanoparticles |
|
|
32 | (1) |
|
|
33 | (1) |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
36 | (1) |
|
|
37 | (1) |
|
|
37 | (1) |
|
|
38 | (1) |
|
|
39 | (1) |
|
|
40 | (5) |
|
Chapter 3 Designing of nanocarriers for liver targeted drug delivery and diagnosis |
|
|
45 | (32) |
|
|
45 | (1) |
|
Physiochemical and biological characteristics of HCC |
|
|
46 | (1) |
|
Morphology and HCC structure |
|
|
46 | (6) |
|
|
52 | (1) |
|
|
53 | (8) |
|
|
61 | (4) |
|
|
65 | (1) |
|
|
66 | (11) |
|
Chapter 4 Nanocarriers-based improved drug delivery for treatment and management of cardiovascular diseases |
|
|
77 | (26) |
|
|
77 | (1) |
|
Nanostructure mediated drug delivery for cardiovascular diseases |
|
|
78 | (1) |
|
Nanocarriers in cardiac arrhythmias |
|
|
78 | (4) |
|
Nanocarriers in thrombosis |
|
|
82 | (2) |
|
Nanocarriers in atherosclerosis |
|
|
84 | (4) |
|
Nanocarriers in aortic aneurysm and other aortic diseases |
|
|
88 | (2) |
|
Nanocarriers in ischemic heart disease and myocardial infarction |
|
|
90 | (2) |
|
|
92 | (3) |
|
|
95 | (8) |
|
Chapter 5 Improved pulmonary drug delivery through nanocarriers |
|
|
103 | (32) |
|
|
103 | (1) |
|
Pulmonary delivery of drugs and lung physiology |
|
|
104 | (2) |
|
Types and classification of nanocarriers used in drug delivery |
|
|
106 | (1) |
|
Organic-based drugs carriers |
|
|
107 | (4) |
|
|
111 | (1) |
|
Organic/inorganic hybrid nanocarriers |
|
|
112 | (1) |
|
General characteristics of nanocarriers |
|
|
112 | (1) |
|
Drug loading and site-specific targeting |
|
|
113 | (1) |
|
Nanocarrier's mechanism and criteria for successful deposition within the respiratory tract upon inspiration |
|
|
114 | (1) |
|
Nanocarriers' mechanism of action and deposition in the respiratory tract upon inspiration |
|
|
115 | (1) |
|
Nanocarriers interaction with lungs' epithelia and macrophages |
|
|
115 | (2) |
|
Nanocarriers' interaction with lung surfactant |
|
|
117 | (1) |
|
Nanocarriers' retention and clearance mechanisms in lungs |
|
|
118 | (1) |
|
Toxicological aspects of inhaled nanocarriers |
|
|
119 | (1) |
|
Pulmonary drug delivery applications of nanocarriers |
|
|
120 | (1) |
|
Polymeric nanoparticles (PNs) in pulmonary drug delivery |
|
|
120 | (1) |
|
Liposomes in pulmonary drug delivery |
|
|
121 | (1) |
|
Solid lipid nanoparticles in pulmonary delivery |
|
|
122 | (1) |
|
Dendrimer-based nanocarriers in pulmonary delivery |
|
|
123 | (1) |
|
Carbon nanotubes (CNTs) for pulmonary drug delivery |
|
|
124 | (1) |
|
|
124 | (1) |
|
|
125 | (8) |
|
|
133 | (2) |
|
Chapter 6 Transdermal drug delivery nanocarriers for improved treatment of skin diseases |
|
|
135 | (32) |
|
|
135 | (1) |
|
|
136 | (1) |
|
|
136 | (1) |
|
|
137 | (1) |
|
|
138 | (1) |
|
|
138 | (1) |
|
Pathways of skin penetration |
|
|
139 | (1) |
|
|
139 | (1) |
|
|
140 | (1) |
|
Transdermal drug delivery (TDD) |
|
|
140 | (1) |
|
Strategies to overcome skin barriers |
|
|
141 | (1) |
|
Passive penetration enhancement techniques |
|
|
142 | (5) |
|
|
147 | (1) |
|
|
148 | (2) |
|
|
150 | (1) |
|
Active permeation enhancement techniques |
|
|
151 | (4) |
|
Application of TDDS for the treatment of skin diseases |
|
|
155 | (1) |
|
|
155 | (2) |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
158 | (1) |
|
|
159 | (8) |
|
Chapter 7 Targeted nano drug delivery systems for renal disorders |
|
|
167 | (10) |
|
|
167 | (1) |
|
Targeted nanocarriers for renal tubulointerstitial diseases |
|
|
168 | (1) |
|
Targeted nanocarriers for glomerular diseases |
|
|
169 | (2) |
|
Targeted nanocarriers for renal cell carcinoma |
|
|
171 | (1) |
|
|
172 | (1) |
|
|
172 | (3) |
|
|
175 | (2) |
|
Chapter 8 Designing of nanocarriers for enhancing drugs absorption through gastrointestinal tract |
|
|
177 | (32) |
|
|
177 | (2) |
|
Biological barriers to oral drug delivery |
|
|
179 | (2) |
|
Absorption mechanisms of nanocarriers in intestine |
|
|
181 | (1) |
|
|
182 | (2) |
|
|
184 | (1) |
|
Design considerations for nanocarriers to a specific section of the GI tract |
|
|
184 | (1) |
|
|
185 | (1) |
|
Small intestine targeting |
|
|
185 | (1) |
|
Intestinal lymphatic targeting |
|
|
186 | (1) |
|
|
187 | (1) |
|
Nanocarriers for enhancing intestinal drug absorption |
|
|
188 | (1) |
|
|
189 | (3) |
|
Lipid or oil based drug carriers |
|
|
192 | (3) |
|
Strategies for intestinal transport improvement of drug nanocarriers |
|
|
195 | (1) |
|
Mucoadhesive nanoparticles |
|
|
195 | (1) |
|
Permeation enhancer nanoparticles |
|
|
196 | (1) |
|
|
196 | (1) |
|
|
197 | (1) |
|
|
197 | (1) |
|
Conclusions and future perspectives |
|
|
198 | (1) |
|
|
199 | (10) |
|
Chapter 9 Nanomaterials as promising therapeutic platform for bone tissues engineering |
|
|
209 | (16) |
|
|
209 | (3) |
|
Nanoparticle-based delivery in bone tissues engineering |
|
|
212 | (1) |
|
Desired features of nanomaterials for bone tissues engineering |
|
|
213 | (1) |
|
Natural polymers based nanomaterials for bone tissues engineering |
|
|
214 | (1) |
|
Natural polymers in bone development |
|
|
214 | (2) |
|
Synthetic biodegradable polymers based nanomaterials for tissue bone regeneration |
|
|
216 | (1) |
|
Inorganic nanoparticles for bone tissues engineering |
|
|
216 | (3) |
|
|
219 | (1) |
|
|
219 | (6) |
|
Chapter 10 Overcoming ocular barriers through nanocarrier-based drug delivery systems |
|
|
225 | (20) |
|
|
225 | (2) |
|
Nanocarrier based ocular drug delivery system |
|
|
227 | (1) |
|
Anterior ocular drug delivery |
|
|
227 | (5) |
|
Posterior ocular drug delivery |
|
|
232 | (8) |
|
|
240 | (1) |
|
|
241 | (4) |
|
Chapter 11 Organ-specific toxicities of nanocarriers |
|
|
245 | (10) |
|
|
245 | (1) |
|
|
246 | (1) |
|
Organ-/tissue-specific nanotoxicity |
|
|
247 | (1) |
|
Toxicity in the pulmonary system |
|
|
247 | (1) |
|
Toxicity in cardiovascular systems |
|
|
248 | (1) |
|
Toxicity in hepatocellular system |
|
|
249 | (1) |
|
Toxicity in the renal system |
|
|
249 | (1) |
|
|
250 | (1) |
|
|
251 | (4) |
Index |
|
255 | |